Quantum Space SPAC Deal S-4/A: $300M PIPE, 12% Preferred, Ghaffarian to Control 78%+ of Votes
IPFX is trading near its 52-week low of $9.95 (0.8% above the low) on light trading volume (0.4× avg).
Summary
Amendment No. 2 to the Quantum Space merger S-4 details a $300 million PIPE (including $240 million of 12% Series A Preferred with full-ratchet anti-dilution), a $600 million equity value for Quantum Space, and Dr. Ghaffarian's expected 78%-84% voting control of the combined NYSE-listed company.
Key Events · M&A and Partnerships · IPFX
-
S-4/A Filed for Quantum Space Merger
Amendment No. 2 to the Form S-4 registers up to 106,680,270 New Quantum Space Class A-1 shares, 6,272,380 Series A Preferred shares and 15,833,333 warrants ahead of the shareholder vote on the $600 million Quantum Space business combination.
-
$300M PIPE With 12% Preferred
The financing comprises a $60 million Pre-Funded Investment (5,882,352 Pre-Funded Preferred Units plus warrants at $12.00) and a $240 million Closing PIPE of 19,999,994 Series A Preferred shares and 19,999,994 Series A Warrants; the preferred pays 12% in kind or 10% in cash and carries full-ratchet anti-dilution with a $7.00 VWAP floor.
-
Ghaffarian to Control 78%-84% of Votes
Through ten-vote Class A-2 and Class B-2 shares, Dr. Ghaffarian is expected to control approximately 78.3% of voting power in the No Redemption Scenario, 80.8% at 50% redemptions and 83.5% at maximum redemptions, making New Quantum Space a NYSE controlled company relying on governance exemptions.
-
TRA Diverts 85% of Tax Savings
The Tax Receivable Agreement requires New Quantum Space to pay the Ghaffarian-affiliated holder 85% of net cash tax savings — roughly $71.4 million of an estimated $84.0 million over 15 years — with an estimated $52.0 million acceleration payment on early termination.
Analysis · IPFX · Manufacturing
This registration statement must go effective before Inflection Point shareholders can vote on the Quantum Space merger, and Amendment No. 2 puts hard numbers on the financing stack for the first time. The combined company raises $300 million of PIPE money — $60 million already funded into Quantum Space and $240 million of 12% Series A Preferred plus warrants at closing — against a $600 million equity value for Quantum Space. That preferred is expensive capital: it pays 12% in kind or 10% in cash, carries full-ratchet anti-dilution, and resets to a 20-day VWAP floor of $7.00 six months after closing, so a weak post-merger share price mechanically hands the preferred holders more stock. Control is the other story: Dr. Ghaffarian is expected to hold roughly 78% to 84% of total voting power through ten-vote Class A-2/B-2 shares, making New Quantum Space a NYSE controlled company exempt from majority-independent board, independent compensation committee and independent nomination rules. Against that, Quantum Space is an early-stage, loss-making business ($24.9 million net loss in 2025) with disclosed material weaknesses in internal controls and going-concern doubt that depends on this deal and the PIPE closing. The $90 million minimum cash condition and the reduced $4 million Cantor fee are the mechanics that determine whether the deal actually closes.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPFX was trading at $10.03 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $338.3M. The 52-week trading range was $9.95 to $11.02. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.